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Available online 13 June 2016Berberine, an isoquinoline plant alkaloid, exhibits awide range of biochemical and pharmacological effects. How-
ever, the precise mechanism of these bioactivities remains poorly understood. In this study, we found signiﬁcant
similarity between berberine and two epigeneticmodulators (CG-1521 and TSA). Reverse-docking using berber-
ine as a ligand identiﬁed lysine-N-methyltransferase as a putative target of berberine. These ﬁndings suggested
the potential role of berberine in epigeneticmodulation. The results of PCR array analysis of epigenetic chromatin
modiﬁcation enzymes supported our hypothesis. Furthermore, the analysis showed that enzymes involved in
histone acetylation and methylation were predominantly affected by treatment with berberine. Up-regulation
of histone acetyltransferase CREBBP and EP300, histone deacetylase SIRT3, histone demethylase KDM6A as
well as histone methyltransferase SETD7, and down-regulation of histone acetyltransferase HDAC8, histone
methyltransferase WHSC1I, WHSC1II and SMYD3, in addition to 38 genes from histone clusters 1–3 were ob-
served in berberine-treated cells using real-time PCR. In parallel, western blotting analyses revealed that the ex-
pression of H3K4me3, H3K27me3 and H3K36me3 proteins decreased with berberine treatment. These results
were further conﬁrmed in acute myelocytic leukemia (AML) cell lines HL-60/ADR and KG1-α. Taken together,
this study suggests that berberine might modulate the expression of epigenetic regulators important for many
downstream pathways, resulting in the variation of its bioactivities.







Chemotherapy plays an important role in the treatment of multiple
myeloma (MM), acutemyelocytic leukemia (AML) and othermalignant
hematological diseases. In recent years, combination chemotherapy and
stem cell transplantation greatly increased the rate of complete remis-
sion in MM and AML. However, improvements were less pronounced
in relapsed patients. The unmet need in this population may be ad-
dressed using optimal chemotherapy combination and novel agents
(Brenner et al., 2008; Jiang et al., 2012; Tallman et al., 2005).
Berberine is a major botanical alkaloid extracted from the roots and
bark of many plants, such as Hydrastis canadensis, Cortex phellodendri
(Huangbai) and Rhizoma coptidis (Huanglian). Recent studies have
shown that berberine induces apoptosis and exerts anti-angiogenic. This is an open access article underactivity in various types of cancer cells. Thismechanism ismainlymedi-
ated via the inhibition of various pro-inﬂammatory cytokines and pro-
angiogenic factors, such as HIF, VEGF, COX-2, NO and NF-κB (Hamsa
and Kuttan, 2012; Kaiser et al., 2006). Zhang et al. (2010) reported
that the pro-apoptotic effects of berberine are closely associated with
the down-regulation of MDM2 followed by a steady-state activation of
p53 in MDM2-overexpressing chemoresistant cancer cells, which play
an important role in treating refractory patients. Berberine also induces
p53-independent, XIAP-mediated apoptotic cell death in p53-null leu-
kemia cells (Liu et al., 2013).
However, how these molecular events are regulated remains ob-
scure. Because the reported events are so diverse, berberine is consid-
ered to regulate upstream rather than downstream molecular
switches. As previously reported, epigenetic changes may play an im-
portant role in the pathogenesis of multiple myeloma and other tumors
(Kaiser et al., 2013). Furthermore, changes in histonemethylation/acet-
ylation may be of particular importance in the pathogenesis of MM and
AML, and targeting enzymes responsible for histone post-translationalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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future (Anon, 2013; Smith et al., 2010). Our experiments independently
conﬁrmed the effect of berberine on growth suppression and cell cycle
cessation and its ability to enhance ROS levels and to inhibit IL6 produc-
tion inmultiplemyeloma cells (HYHu, data to be published separately).
Our bioinformatics analysis suggested that berberine altered epigenetic
patterns inmultiplemyelomaU266 cells. Experimental validations sup-
port ourworking hypothesis that berberinemay regulate the epigenetic
switches that govern diverse downstreambioactivities and suppress the
growth of AML cells except U266 cells. Taken together, these ﬁndings
may shed new light on the mechanism underlying berberine activation
of various biological events, including, but not limited to, its anti-cancer
activities.
2. Materials and methods
2.1. Cell line and reagents
Themultiplemyeloma cell line U266was kindly provided by Profes-
sor Jie Jin (HematologyDepartment of The First AfﬁliatedHospital,Med-
icine College, Zhejiang University). HL-60/ADR and KG1-α cell lines
were obtained from the Institutes for Biological Sciences Cell Resource
Center, Chinese Academy of Sciences, Shanghai, China. The cells were
maintained in RPMI1640 (Gibco, USA) supplementedwith 10% fetal bo-
vine serum (FBS; Gibco) at 37 °C in a 5% CO2 incubator. Concentrated
stock solutions of berberine (Sigma-Aldrich, USA) were diluted in
DMSO (Sigma-Aldrich, USA). RNA-grade TRIzol was purchased from
Invitrogen (CA, USA). The RevertAid™ First Strand cDNA Synthesis Kit
and SYBR Premix Ex Taq II kit were obtained from Fermentas (USA)
and Takara (Japan), respectively.
2.2. Antibodies
The primary antibodies used in this study were the following: anti-
H3K4me2 polyclonal antibody (CST, #9726), anti-H3K4me3 polyclonal
antibody (Abcam, #ab8580), anti-H3K27me3 monoclonal antibody
(CST, #9733), anti-H3K36me3 monoclonal antibody (CST, #4909), and
anti-Histone3 monoclonal antibody (CST, #3377).
2.3. RNA extraction
U266 cellswere seeded in 75 cm2 plates at a concentration of 1 × 107
cells/plate and were treated for 48 h with berberine at ﬁnal concentra-
tions of 0, 40, 80, 120 and 160 μM. In addition, the concentrations of ber-
berine used in HL-60/ADR and KG1-α cells were 0, 11, 22, and 44 μM
due to different IC50s (half maximal inhibitory concentration). RNA
was extracted using TRIzol (Invitrogen, USA) according to the
manufacturer's recommended protocol. The quantity and purity of
RNA were determined by measuring A260 and A280 using a NanoDrop
ND-1000 (NanoDrop). The integrity of the RNA was determined using
1.5% agarose gel electrophoresis.
2.4. Gene expression microarray
Total RNA was separately harvested and puriﬁed from U266 cells of
the control group and berberine (120 μM)-treated group. RNA sample
ampliﬁcation and labeling were performed using the Amino Allyl
MessageAmp™ II aRNA Ampliﬁcation Kit (Ambion, Inc.) according to
the manufacturer's instructions. Samples (4 μg) labeled with Cy3/Cy5
were hybridized and processed on Chipscreen (Shenzhen, China) oper-
on human oligo microarray CSC-GE-30, which covered ~35,000 tran-
scripts. Scanning was performed with the LuxScan™ 10 K Microarray
Scanner under settings recommended by CapitalBio (Beijing, China).
After removal of negative-ﬂagged probes and data normalization
using R's “limma” package, differential genes were selected based on
the fold-change for functional enrichment using R programming(www.cran.r-project.org) and the Nextbio platform (www.nextbio.
com). Gene set enrichment was performed using our in-house web
tool, in which the main data sources were provided by MSigDB (Broad
Institute), Reactome, Biocarta and Gene Ontology Consortium, in addi-
tion to the gene sets collected from literature mining.
2.5. PCR array analysis of epigenetic chromatin modiﬁcation enzymes
To proﬁle the gene expression of epigenetic chromatin modiﬁcation
enzymes, we employed Epigenetic Chromatin Modiﬁcation Enzymes
PCR Array (SABiosciences, QIAGEN). The array covers 84 genes of epige-
netic factors from several families, including ﬁve housekeeping genes
(B2M, HPRT1, RPL13A, GAPDH, ACTB). The PCR array was performed
by Shanghai Kangchen Biotech Company (Shanghai, China). For this ex-
periment, U266 cells were treated with 80 μM of berberine for 48 h. An
RT2 First Strand Kit (SABiosciences) was used to prepare cDNAs from
the RNA samples. Next, cDNAs were added to the RT2 qPCR Master
Mix, containing SYBRGreen and reference dye, and subsequently ampli-
ﬁed for 10 min at 95 °C, 40 PCR cycles (15 s at 95 °C, 1 min at 60 °C) ac-
cording to the manufacturer's recommended protocol. After the PCR
reaction, B2M, RPL13A and ACTB were used as internal references for
data normalization.
2.6. Growth inhibition and apoptosis assay
Cells were respectively treated with different concentrations of BBR
(berberine). Antiproliferative effect was assessed by employing MTS (a
soluble tetrazolium salt) assay. Cells were cultured for 20, 44, 68 and
68 h in 96-well microtiter plates with different concentrations of BBR.
Then, theMTSwas added and the incubation Cell Titer continued for ad-
ditional 4 h. Absorbance was measured at 490 nm using a spectropho-
tometer (BIO-RAD 680, USA), and cell viability was determined in
each group and compared with that of the untreated cells. After 48 h
culture, untreated and drug-treated cells were collected, and washed
twice with cold PBS (pH 6.9, each for 5 min), stained with Annexin V-
FITC/PI (NanJing KeyGen Biotechnology, NanJing, China), and subjected
to ﬂow cytometry (Becton Dickinson, CA, USA) analysis of apoptosis.
2.7. Real-time PCR
Additional PCR reactions were performed to cover a few more se-
lected genes. The cDNAs were synthesized using reverse transcription
from 0.5 μg total RNAs using oligo (dT) primers. Real-Time PCR reac-
tions were performed using the SYBR Green PCR Master Mix (Takara)
on a LightCycler480 System(Roche). The primer sequences for the chro-
matinmodiﬁcation genes and house-keeping geneGAPDH are provided
in Supplementary data 1.
2.8. Western blotting analysis
Berberine was added to U266 cells at ﬁnal concentrations of 0, 40,
80, 120 and 160 μM for 24 h. In addition, HL-60/ADR and KG1-α cells
were treated with 0, 11, 22 μM berberine for 48 h. Protein concentra-
tions of the SDS lysates were determined using the bicinchoninic acid
method (Tjabringa et al., 2003).
2.9. Statistical analyses
Each experiment was performed in triplicate and repeated at least
three times. All data from these experiments were expressed as the
mean ± S.E.M using SPSS13.0 software. The difference among the
means of multiple groups was analyzed using one-way analysis of var-
iance (ANOVA) followed by the Tukey test and LSD testwhen equal var-
iances were assumed, while Dunnett's T3 test and Dunnett's C test were
used when equal variances were not assumed. A difference was deﬁned
as signiﬁcant at p b 0.05.
Table 1
Results of epigenetic chromatin modiﬁcation enzymes PCR array.
Family Up-regulation Down-regulation
DNA methyltransferase DNMT1/3B
Histone acetyltransferase CREBBP, EP300, HAT1,
NCOA, KAT








Histone phosphorylation AURKC AURKB




The p values (p b 0.05) were calculated based on Student's t-test comparing replicate 2−
△△Ct values for each gene between the control and the treatment groups. Genes showing
at least 1.5-fold change were listed.
a Inconsistency between PCR array RT-qPCR and microarray.
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3.1. Berberine induced gene expression changes in the epigenome
Global changes in gene expression induced by berberine in U266 cells
were examined using the Chipscreen operon human oligo microarray,
which covers approximately 35,000 transcripts of the human genome.
Compared with the control group, 2599 genes were up-regulated and
2155 genes were down-regulated at least two-fold with berberine treat-
ment. Gene set enrichment analysis showed that 38 genes (p≈ 0) from
histone clusters 1–3, particularly in cluster 1, were down-regulated uponFig. 1. BBR inhibits cell growth and induce apoptosis in HL-60/ADR and KG1-α cells. After exp
measured by MTS assay. Viability of HL-60/ADR and KG1-α cells (B) after exposed to BBR fo
cytometry to determine apoptotic cells, including early apoptotic cells (lower right quadrant)
means KG1-α cells.berberine treatment (Supplementary data 3). These genes are tightly as-
sociated with nucleosome assembly (p b 0.05) as well as telomere main-
tenance (p b 0.05) and, thus, are important for epigenetic regulation.
Many gene sets associated with the polycomb complex 1/2 and DNA
methylation, which regulate downstreampathways such as TNF-mediat-
ed apoptosis, NF-κB, Jak-STAT, and ERK/AKT, are also enriched (Supple-
mentary data 4). Consistent with these ﬁndings, the expression of
histone deacetylases HDAC8 and HDAC9 was also down-regulated. In
contrast, the expression of histone acetyltransferase (HAT) P300/CBP
was up-regulated upon berberine treatment. In addition, large portions
of gene groups related to terms such as “HDAC (histone deacetylase)”
or “berberine”, found using the literature mining tool FABLE (www.
fable.chop.edu), demonstratedmany intersections with the genes identi-
ﬁed in this study (Supplementary data 2C), thereby strongly suggesting a
non-random association among the genes.
3.2. Reverse-docking for berberine
To identify the putative molecular targets of berberine, we per-
formed a reverse docking experiment to predict drug targets based on
the docking of the 3D structure of berberine against a collection of 3D
structures of known proteins (Li et al., 2006). This docking identiﬁed ly-
sine-N-methyltransferase as a putative candidate targeted by berberine
(Supplementary data 5).
3.3. Effects of berberine on epigenetic regulators
Because the above two analyses suggested the potential involve-
ment of berberine in epigenetic regulation, we performed PCRosed to different concentration BBR for 24, 48, 72, 96 h, HL-60/ADR cells (A) viability was
r 48 h were compared. Cells were stained with Annexin V-FITC/PI and subjected to ﬂow
and late apoptotic cells (upper right quadrant) (C); HA means HL-60/ADR cells, and KG
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be epigenetic regulators. The PCR array of the human epigenetic chro-
matin modiﬁcation enzymes allows the proﬁling of the expression of
84 key genes that encode enzymes, which are known or predicted to
modify genomic DNA and histone substrates to regulate chromatin ac-
cessibility and gene expression. We quantiﬁed the expression of these
geneswith at least 1.5-fold change inU266 cellswith orwithout berber-
ine. As summarized in Table 1, several key observationsweremade: (1)
Five histone acetylase levels represented by EP300 and CREBBP were
up-regulated, whereas at least two histone deacetylase levels, HDAC2
andHDAC8, were reduced; (2) the lysine (K)-speciﬁc demethylase fam-
ily was fairly active, among which KDM1 targets H3K9me2/1 and
H3K4me2/1, KDM4 demethylates both H3K9me3/2 and H3K36me3/2,
HDM5 is speciﬁc for H3K4me3/2 and KDM6 targets H3K27me3/2; and
(3) the SET domain-containing histone methyltransferase family was
also fairly active. SET1 and SET7methylate H3K4, whereas SETBmethyl-
ates H3K9. Both SET2 and SET3 methylate H3K36. SET6 mono-methyl-
ates K310 of the RelA subunit of the NF-κB complex. SETD8 mono-
methylates H3K20, and SMYD3 di- and tri-methylates H3K4. However,
there is a discrepancy for SMYD3 expression between microarray and
PCR array data. After conﬁrming the results using RT-qPCR, we foundFig. 2.Quantiﬁcation of gene expression by Real-time PCR. HumanmultiplymyelomaU266 cells
RNAs. PCR reactionwas done as described inMaterials andmethods section. RelativemRNA leve
SIRT3 (H), SMYD3 (I) were measured respectively. The real-time PCR results were standardized
for p b 0.01.that SMYD3 was down-regulated and not up-regulated by berberine;
(4) DNAmethyltransferases, which are responsible for de novomethyl-
ation (DNMT3) ormaintenance of methylated CpG (DNMT1), were also
down-regulated (Table 1).3.4. Berberine induces cytotoxicity and apoptosis in HL-60/ADR and KG1-α
cells
We examined the effect of berberine on the cell viability using the
MTS assay in AML lines (Fig.1A). HL-60/ADR cells were treated with dif-
ferent concentrations of BBR for 24, 48, 72 and 96 h. Based on the
growth inhibition assay, BBR inhibit cell growth obviously in HL-60/
ADR cells after 48 h exposed. When KG1-α cells were exposed to
same concentrations of BBR, the survival rate was higher than HL-60/
ADR cells (Fig.1B). HL-60/ADR cells were treated with 1 μM and 11 μM
BBR, for 48 h, and stained with Annexin V-FITC/PI. Apoptosis was deter-
mined by ﬂow cytometry, including early apoptotic cells (Annexin V-
FITC positive, PI negative) and late apoptotic cells (Annexin V-FITC
and PI positive). Berberine exhibited weekly cytotoxic activity in the
KG1-α cells (Fig.1C).were incubatedwith 0, 40, 80, 120, 160 μMof berberine for 48 h prior to extraction of total
ls of CREBBP (A), EP300 (B), HDAC8 (C), KDM6A (D),WHSC1І (E),WHSC1II (F), SETD7 (G),
against GAPDH, and the relative ratios were calculated. **: signiﬁcant difference observed
Fig. 4. Semi-quantitative assessment of H3K4me2, H3K4me3, H3K27me3, H3K36me3
protein levels by Western blot analysis. Lanes 1–5: cells were incubated with 0, 20, 40,
80, 120 μM of berberine for 24 h. Protein samples were prepared and histone
modiﬁcations were quantiﬁed as described in Materials and methods section. Level
detected by anti-Histone3 (top) was used as internal reference for normalization. The
proteins Histone3, H3K4me2, H3K4me3, H3K27me3 and H3K36me3 were the expected
size of 17KDa.
Fig. 3. Quantiﬁcation of gene expression by Real-time PCR. HL-60/ADR and KG1-α cells were incubated with 0, 11, 22 μM of berberine for 48 h prior to extraction of total RNAs. Relative
mRNA levels of CREBBP (A), EP300 (B), HDAC8 (C), KDM6A (D), WHSC1І (E), WHSC1II (F), SETD7 (G), SIRT3 (H), SMYD3 (I) weremeasured respectively. The real-time PCR results were
standardized against GAPDH, and the relative ratios were calculated. **: signiﬁcant difference observed for p b 0.01, *: signiﬁcant difference observed for p b 0.05.
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Conﬁrmation of the PCR array experiment was performed
using standard quantitative real-time PCR (qRT-PCR). We select-
ed genes to further examine based on the PCR array results, as
well as their potential function on epigenetic changes in previous
reports. To conﬁrm the universality of epigenetic regulation of
berberine in hematological malignancy, we also conﬁrmed gene
expression using qRT-PCR in AML cell lines, HL-60/ADR and
KG1-α.
The mRNA expression of CREBBP, EP300 and SIRT3, all of which
are members of class III histone acetyltransferases (HDACs), was sig-
niﬁcantly higher in the berberine-treated group compared to the
control group, whereas class I HDACs, which are represented by
HDAC8, showed lower mRNA expression in the berberine-treated
group (Fig. 2). The expression of histone methyltransferase and
demethylase mRNA were also measured. Our data showed that
SETD7 and KDM6A were up-regulated, while WHSC1I, WHSC1II
and SMYD3 were down-regulated, upon treatment. These results
were consistent with the results obtained from the qRT-PCR and
PCR array, except for the high expression of SMYD3, which was
down-regulated in both the microarray and qRT-PCR experiments,
presumably due to an experimental error in the PCR array. Similar
results were observed in HL-60/ADR and KG1-α cells. However, the
only difference was the expression of WHSC1I, which was higher
after berberine treatment, and there was no difference in HDAC8
(Fig. 3).3.6. Berberine affects the level of H3K4me2, H3K4me3, H3K27me3, and
H3K36me3 proteins
Similar to other post-translationalmodiﬁcations,methylation of var-
ious lysine (K) residues on histones, particularly on histone3 (H3) could
Fig. 5. Semi-quantitative assessment of H3K27me3 protein levels by Western blot
analysis. Picture A and B correspond to HL-60/ADR cells and KG1-α cells, respectively.
Lanes 1–3: cells were incubated with 0, 11, 22 μM of berberine for 48 h. Protein samples
were prepared and histone modiﬁcations were quantiﬁed as described in Materials and
methods section. Level detected by anti-Histone3 (top) was used as internal reference
for normalization.
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ty. H3K27 and H3K9 are often associated with gene silencing, whereas
H3K4 and H3K36 are often linked with the active transcribing region
(Bartova et al., 2008). On the basis of the altered expression proﬁles of
genes participating in methylation or demethylation by berberine, we
examined whether berberine treatment affects the methylation status
of histone 3 protein in U266 cells. Thus, the protein levels of methylated
histone H3K4me2, H3K4me3, H3K27me3, and H3K36me3 were mea-
sured semi-quantitatively using western blot analysis. Most of these
protein expressions trended lower as concentrations of berberine in-
creased, with the exception of H3K4me2 (Fig. 4). In HL-60/ADR and
KG1-α cells, the protein levels of H3K27me3 were reduced after treat-
ment of berberine (Fig. 5).
4. Discussion
The epigenetic-regulating effects of berberine have not yet been
studied. On the basis of the bioinformatics analyses, predictions and ex-
perimental validations, our present study demonstrates the potential of
berberine as an epigenetic modulator. Many gene sets associated with
polycomb complex 1/2 epigenetic regulation were enriched byFig. 6. A hypothetical model of epigenetic regulation by berberine on epigenetic chromatin m
protein levels of methylation of H3K4, H3K27, H3K36 by altering levels of several families of
Dash line: inhibition; solid line: activation.berberine (Supplementary data 4). Our data supported the hypothesis
(Fig. 6) that berberine interacts with master regulators or interferes
with the formation of regulatory complexes in chromatin remodeling,
which is responsible for the control of downstream bioactivities, such
as cell cycle, apoptosis, and mechanisms related to metabolic disorders,
and immune response. Histone acetylation is an important post-transla-
tional modiﬁcation in the regulation of gene expression. CBP and p300
proteins, which exhibit acetylase activity, are transcriptional co-activa-
tors and hematopoietic tumor suppressors. Their loss may result in ab-
errant differentiation or directly affect acetylation targets, such as p53
and TCF(Kung et al., 2000). However, HDACs are more often related to
gene silencing. HDAC8 is overexpressed in childhood acute lymphoblas-
tic leukemia (ALL) compared with normal bone marrow cells (Moreno
et al., 2010). HDAC8 may also mediate invasion and up-regulate
MMP-9 expression in breast cancer (Park et al., 2011). Here, we ob-
served that berberine up-regulated the expression of CBP, EP300 and
SIRT3 and down-regulated the expression of HDAC8 in U266 cells. In
HL-60/ADR and KG1-α cells, CBP, EP300, SIRT3 were also up-regulated,
but HDAC8 did not have signiﬁcant changes and was WHSC1І up-regu-
lated on the contrary. Interestingly, SIRT3 can function as a context-de-
pendent tumor-speciﬁc promoter or suppressor. For example, SIRT3
suppresses tumorigenesis and induced cell death in colorectal carcino-
ma, osteosarcoma, leukemia, and breast cancer, as reviewed by Turki
Y (Alhazzazi et al., 2011). Our study suggested that berberine induces
histone acetylation andmay result in the activation of genes that are re-
sponsible for growth suppression and apoptosis in U266, HL-60/ADR
and KG1-α cells.
Wolf–Hirschhorn syndrome candidate gene 1 (WHSC1; also known
as NSD2 andMMSET) has been reported tomethylate H3K36, aswell as
H4K20, H3K4 and H3K27 proteins (Wagner and Carpenter, 2012).
WHSC1-mediated disruption of H3K36me2 protein organization may
promote oncogenic programming in many cell types, particularly in
multiple myeloma. In myeloma cells, the expression of WHSC1 is asso-
ciated with global H3K36me2 protein levels and the cell proliferationodiﬁcation enzymes. From this study, we propose a model in which berberine modulates
speciﬁc modiﬁcation enzymes, and thus turning on/off downstream targets/pathways.
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tion decreases H3K36me2 andH3K36me3 levels, which is accompanied
by a concomitant decrease in the global levels of H3K27me2 and
H3K27me3 proteins (Wagner and Carpenter, 2012). Our results showed
that berberine reduced the levels of H3K27me3 and H3K36me3 pro-
teins in U266 cells, reduced the mRNA expression of WHSC1, and in-
creased the mRNA expression of KDM6A, whose product acts as a
histone demethylase speciﬁc for H3K27me3/2 proteins. Bi-allelic so-
matic mutations and down-regulation of KDM6A have been described
in multiple tumor types, and low KDM6A activity is correlated with
poor prognosis (Lim et al., 2010). Recently, it was hypothesized that
an increase in H3K27 methylation, via either WHSC1 overactivity or
loss of KDM6A function, is advantageous to myeloma cell proliferation
(Kim et al., 2008; Smith et al., 2010). The present study demonstrated
the effects of berberineon the suppression of cell growth andpromotion
of cell differentiation by decreasing H3K36me3 protein levels via the
down-regulation ofWHSC1 and/or up-regulation of KDM6A expression
in U266, HL-60/ADR and KG1-α cells.
Methylation of lysine 4 (K4) on H3 is associated with euchromatic
regions and H3K4 tri-methylation (H3K4me3) in general, which
marks actively transcribed genes. However, H3K4me3 and H3K27me3
proteins often readily form the so-called “bivalent” histonemarks for si-
lenced genes for transcription. H3K4me2 and H3K4me3 levels are in-
creased in many cancers (Chen et al., 2011; Ellinger et al., 2010).
Jugova et al. (2011) observed that compared with leukemia cells,
H3K4 methylation in MM cells is more susceptible to selective inhibi-
tion of HDACs and DNMTs. Histonemethyltransferase SMYD3, a histone
H3K4 speciﬁc di- and tri-methyltransferase, has been reported to re-
press tumor suppressors while promoting oncogenes (e.g., N-myc,
CrkL, Wnt10b, RIZ and hTERT) and genes involved in the control of
cell cycle (e.g., CCNG1 and CDK2) or signal transduction (e.g., STAT1,
MAP3K11 and PIK3CB) (Cock-Rada et al., 2012; Foreman et al., 2011;
Hamamoto et al., 2004; Ren et al., 2011). Although the SMYD3 expres-
sion observed in our PCR array experiment appeared aberrant, we con-
ﬁrmed a consistent reduction in SMYD3 mRNA expression in an
independent PCR experiment (Fig. 2), which was consistent with ﬁnd-
ings of decreased levels of H3K4me3 protein after berberine treatment.
These ﬁndings suggest that berberine potentially reduces the levels of
H3K4me3 protein by down-regulating SMYD3 expression.
5. Conclusion
We conclude that the antitumor effects of berberinemay result from
themodulation of key epigenetic regulators. This offers a novel explana-
tion of howberberine initiates somany therapeutic activities in the clin-
ic. Although our bioinformatics and experimental study supports this
working hypothesis, additional experiments should be performed to
conﬁrm these ﬁndings (e.g., to dissect the interplay between berberine
and its target(s) and the downstream signaling cascade).
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